Management of hepatitis c before and after liver transplantation in the era of rapidly evolving therapeutic advances

Journal of Clinical and Translational Hepatology

Volumn 2, Issue 2, 2014, Pages 124-133

  Bunchorntavakul, Chalermrat ^a   Reddy, K Rajender ^b  

^a RANGSIT UNIVERSITY   (Thailand)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hepatitis C; Immunosuppression; Interferon; Liver transplantation; Prevention; Protease inhibitors; Treatment

Indexed keywords

EID: 84964657986     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2014.00002     Document Type: Review

References (88)

1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513– 521. doi: 10.1053/j.gastro.2009.09.067.
2. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008;14 (Suppl 2):36–44. doi: 10.1002/lt.21646.
3. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009;9:1707–1713.
4. Bunchorntavakul C, Bonnel AR, Reddy KR. Management of hepatitis before and after liver transplantation. In: Arroyo V, editor. Management of Hepatitis C: International Hepatology Updates Series. Barcelona: Permanyer Publications; 2011.
5. Reddy KR, Bunchorntavakul C. Managing hepatitis C: before and after liver transplantation. Indian J Transplant 2011;5:72–76.
6. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C– natural history and cofactors. Aliment Pharmacol Ther 2005;22 (Suppl 2): 74–78. doi: 10.1111/j.1365-2036.2005.02602.x.
7. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889–896. doi: 10.1053/gast.2002.32418.
8. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011;53:317–324. doi: 10.1002/hep.24074.
9. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007;14 (Suppl 1):89–96. doi: 10.1111/j.1365-2893.2007.00920.x.
10. Ackefors M, Nystrom J, Wernerson A, Gjertsen H, Sonnerborg A, Weiland O. Evolution of fibrosis during HCV recurrence after liver transplantation– influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. J Viral Hepat 2013;20:770–778.
11. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680–687. doi: 10.1053/jhep.2002.31773.
12. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010;16:1228–1235. doi: 10.1002/lt.22175.
13. Neff GW, Shire N, Ruiz P, O’Brien C, Garcia M, Dela Garza J, et al. The importance of clinical parameters when differentiating cholestatic hepatitis C virus from allograft rejection. Transplant Proc 2005;37:4397–4402. doi: 10.1016/j.transproceed.2005.10.012.
14. Bellido-Munoz F, Giraldez-Gallego A, Roca-Oporto C, Garcia-Cayuela T, Pascasio-Acevedo JM, Sousa-Martin JM. Monitoring the natural evolution and response to treatment of post liver transplant recurrent hepatitis C using transient elastography: preliminary results. Transplant Proc 2012;44:2082– 2086. doi: 10.1016/j.transproceed.2012.07.090.
15. J S Cross T, Jothimani D, Heneghan MA, Harrison PM. Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence. Clin Transplant 2011;25:345–351. doi: 10.1111/j.1399-0012.2011.01396.x.
16. Cholongitas E, Tsochatzis E, Goulis J, Burroughs AK. Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. Transpl Int 2010;23:861–870. doi: 10.1111/j.14322277.2010.01142.x.
17. Rigamonti C, Donato MF, Colombo M. Transient elastography in the early prediction of progressive recurrent hepatitis C following liver transplantation. Hepatology 2010;52:800–801. doi: 10.1002/hep.23607.
18. Crespo G, Lens S, Gambato M, Carrion JA, Marino Z, Londono MC, et al. Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C. Am J Transplant 2014;14:375–383. doi: 10.1111/ajt.12594.
19. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl 2008;14 (Suppl 2):S58–66. doi: 10.1002/lt.21624.
20. Roche B, Samuel D. Hepatitis C virus treatment pre-and post-liver transplantation. Liver Int 2012;32 (Suppl 1):120–128. doi: 10.1111/j.1478-3231.2011.02714.x.
21. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, Carrion JA, Martinez SM, Sanchez-Tapias JM, et al. Donor and Recipient IL28B Polymorphisms in HCVInfected Patients Undergoing Antiviral Therapy before and after Liver Transplantation. Am J Transplant 2011;11:1051–1057.
22. Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009;50:719–728. doi: 10.1016/j.jhep.2008.11.015.
23. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804– 811. doi: 10.1001/jama.2013.109309.
24. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405–2416.
25. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417–2428.
26. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207–1217.
27. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195–1206.
28. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatmentnaive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013;58:1918–1929. doi: 10.1002/hep.26641.
29. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) NCT01514890. J Hepatol 2013;59:434–441. doi: 10.1016/j.jhep.2013. 04.035.
30. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, et al. Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus the NS5A Inhibitor Ledipasvir or the NS5B Non-nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. Gastroenterology 2014;146:736–743. doi: 10.1053/j.gastro.2013.11.007.
31. Kwo PY, Tector AJ. Oral direct-acting antiviral therapy to prevent reinfection of the liver graft after liver transplantation for hepatitis C virus-related cirrhosis. Liver Transpl 2013;19:780–781. doi: 10.1002/lt.23662.
32. Curry MP, Forns X, Chung RT, Terrault N, Brown RS, Fenkel JM, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013;58:314A.
33. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1–9. doi: 10.1053/jlts.2003.50268.
34. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005;11:941–949. doi: 10.1002/lt.20405.
35. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006;12: 1381–1389. doi: 10.1002/lt.20876.
36. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol 2010;52:951–952. doi: 10.1016/j.jhep.2010.02.002.
37. Gurusamy KS, Tsochatzis E, Toon CD, Davidson BR, Burroughs AK. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2013;12: CD006573.
38. Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53–59. doi: 10.1016/j.jhep.2005.02.015.
39. Zimmermann T, Bocher WO, Biesterfeld S, Zimmermann A, Kanzler S, GreifHiger G, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007;20:583–590. doi: 10.1111/j.14322277.2007.00481.x.
40. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, et al. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011;17:528–538. doi: 10.1002/lt.22271.
41. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008;8:2426–2433.
42. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679–687.
43. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274–287. doi: 10.1016/j.jhep.2008.05.002.
44. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006;6:1586– 1599.
45. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008;15:699–709. doi: 10.1111/j.1365-2893.2008.01019.x.
46. Lange CM, Moradpour D, Doehring A, Lehr HA, Mullhaupt B, Bibert S, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011;55:322–327. doi: 10.1016/j.jhep.2010.10.037.
47. Firpi RJ, Dong H, Clark VC, Soldevila-Pico C, Morelli G, Cabrera R, et al. CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int 2013;33:72–78. doi: 10.1111/liv.12013.
48. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008;14:53–58. doi: 10.1002/lt.21312.
49. Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and Idiosyncratic Hepatotoxicity in the Liver Transplant setting. J Hepatol 2014; 60:872–884.
50. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007;7: 2816–2820.
51. Garg V, van Heeswijk R, Lee JE, Nadkarni KA, Luo X. The effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20–27. doi: 10.1002/hep.24443.
52. Charlton M, Dick T. Victory and defeat at Heraclea-Treating hepatitis C infection following liver transplantation with telaprevir and boceprevir. J Hepatol 2014;60:6–8. doi: 10.1016/j.jhep.2013.10.006.
53. Coilly A, Furlan V, Roche B, Barau C, Noel C, Bonhomme-Faivre L, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012;56:5728–5734. doi: 10.1128/AAC.01151-12.
54. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J Hepatol 2014;60:78–86. doi: 10.1016/j.jhep.2013.08.018.
55. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012;18:1464–1470. doi: 10.1002/lt.23542.
56. Hulskotte E, Gupta S, Xuan F, van Zutven M, O’Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012;56:1622–1630. doi: 10.1002/hep.25831.
57. Reddy KR, Everson GT. Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation. Hepatology 2013;58: 1181–1184. doi: 10.1002/hep.26612.
58. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, et al. Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results. PLoS One 2013;8:e80528. doi: 10.1371/journal.pone.0080528.
59. Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation. J Hepatol 2012;56:288–290. doi: 10.1016/j.jhep.2011. 06.012.
60. Charlton M, Gane EJ, Manns MP, Brown RS, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Hepatology, 2013; 58(Suppl): 1378A.
61. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012;18:1053–1059. doi: 10.1002/lt.23482.
62. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013;13: 1601–1605. doi: 10.1111/ajt.12209.
63. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010;8:1017–1029. doi: 10.1016/j.cgh.2010.08.026.
64. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011;55:207–217. doi: 10.1016/j.jhep.2010.11.012.
65. Charco R, Vargas V, Allende H, Edo A, Balsells J, Murio E, et al. Is hepatitis C virus recurrence a risk factor for chronic liver allograft rejection? Transpl Int 1996;9 (Suppl 1):S195–197. doi: 10.1111/j.1432-2277.1996.tb01606.x.
66. Ueda Y, Kaido T, Ito T, Ogawa K, Yoshizawa A, Fujimoto Y, et al. Chronic Rejection Associated with Antiviral Therapy for Recurrent Hepatitis C after Living-Donor Liver Transplantation. Transplantation 2014;97:344–350. doi: 10.1097/01.TP.0000435702.61642.0a.
67. Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008;14:861–871. doi: 10.1002/lt.21447.
68. Casanovas T, Argudo A, Pena-Cala MC. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports. Transplant Proc 2011; 43:2233–2236. doi: 10.1016/j.transproceed.2011.05.028.
69. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13:1521–1531. doi: 10.1002/lt.21182.
70. Villamil F, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, et al. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant Proc 2006;38:2964–2967. doi: 10.1016/j.transproceed.2006.08.131.
71. Berenguer M, Aguilera V, San Juan F, Benlloch S, Rubin A, Lopez-Andujar R, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010;90:1204–1209. doi: 10.1097/TP.0b013e3181fa93fa.
72. Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol 2012;56:973–983. doi: 10.1016/j.jhep.2011.06.031.
73. Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation 2006;82:579–580. doi: 10.1097/01.tp.0000229397.81425.51.
74. Firpi RJ, Soldevila-Pico C, Morelli GG, Cabrera R, Levy C, Clark VC, et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010;55:196–203. doi: 10.1007/s10620-009-0981-3.
75. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006;6:1578–1585.
76. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006; 131:1452–1462. doi: 10.1053/j.gastro.2006.08.027.
77. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005;11:750–759. doi: 10.1002/lt.20453.
78. Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, et al. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transpl 2013;19:896–906. doi: 10.1002/lt.23679.
79. Asthana S, Toso C, Meeberg G, Bigam DL, Mason A, Shapiro J, et al. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011;25:28–34.
80. Chan AJ, Lake JR. Immunosuppression in HCV-positive liver-transplant recipients. Curr Opin Organ Transplant 2012;17:648–654. doi: 10.1097/MOT.0b013e32835a2b5a.
81. Wagner D, Kniepeiss D, Schaffellner S, Jakoby E, Mueller H, FahrleitnerPammer A, et al. Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates. Int Immunopharmacol 2010;10:990– 993. doi: 10.1016/j.intimp.2010.05.006.
82. Kelly MA, Kaplan M, Nydam T, Wachs M, Bak T, Kam I, et al. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. Transplant Proc 2013;45:3325–3328. doi: 10.1016/j.transproceed.2013.04.011.
83. McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011;11:2379–2387.
84. Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012;18:1029–1036. doi: 10.1002/lt.23479.
85. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401. doi: 10.1038/nature08309.
86. Carrion JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010;53:962–970. doi: 10.1016/j.jhep.2010.06.006.
87. Ghabril M, Dickson R, Wiesner R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection. Am J Transplant 2008;8:404–411.
88. Andres A, Gerstel E, Combescure C, Asthana S, Merani S, Majno P, et al. A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis. Transplantation 2012;93:717–722. doi: 10.1097/TP. 0b013e318246f8b3.